Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of (TAK) Institutional Holders & Insider Trades

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

TAK · NYSE

100 filers$1.48B loaded

Manager	Filing date	Shares	Value	Change
Capital Research Global Investors	Mar 31, 2026	19.10M	$316.37M	+41.65%
Fmr Llc	Mar 31, 2026	7.12M	$117.87M	+75.44%
Morgan Stanley	Mar 31, 2026	6.47M	$107.14M	+1.51%
Adage Capital Partners Gp, L.L.C.	Mar 31, 2026	6.42M	$106.40M	0.00%
Goldman Sachs Group Inc	Mar 31, 2026	5.62M	$93.05M	+16.93%
Brandes Investment Partners, Lp	Mar 31, 2026	4.43M	$73.37M	+14.14%
Blackrock, Inc.	Mar 31, 2026	3.18M	$52.60M	+16.28%
Arrowstreet Capital, Limited Partnership	Mar 31, 2026	3.12M	$51.61M	-45.16%
Renaissance Technologies Llc	Mar 31, 2026	2.99M	$49.50M	+14.16%
Ubs Group Ag	Mar 31, 2026	2.74M	$45.38M	-33.55%
D. E. Shaw & Co., Inc.	Mar 31, 2026	2.60M	$43.10M	-39.39%
Van Eck Associates Corp	Mar 31, 2026	2.26M	$37.43M	-1.97%
First Trust Advisors Lp	Mar 31, 2026	1.97M	$32.64M	-17.27%
Northern Trust Corp	Mar 31, 2026	1.96M	$32.48M	+15.43%
Managed Asset Portfolios, Llc	Mar 31, 2026	1.80M	$29.78M	+20.23%
Envestnet Asset Management Inc	Jun 30, 2026	1.60M	$26.47M	+13.19%
Quantinno Capital Management Lp	Mar 31, 2026	1.29M	$21.35M	+20.57%
Wells Fargo & Company/Mn	Mar 31, 2026	1.14M	$18.81M	+7.13%
Aqr Capital Management Llc	Mar 31, 2026	894.42K	$14.81M	+31.67%
Capital Wealth Planning, Llc	Mar 31, 2026	886.84K	$14.69M	0.00%
Crossmark Global Holdings, Inc.	Jun 30, 2026	783.84K	$12.98M	+0.86%
Stifel Financial Corp	Mar 31, 2026	628.55K	$10.41M	+13.40%
Citadel Advisors Llc	Mar 31, 2026	624.16K	$10.34M	+60.15%
Royal Bank Of Canada	Mar 31, 2026	614.85K	$10.18M	+10.96%
Creative Planning	Mar 31, 2026	543.00K	$8.99M	+37.33%
Charles Schwab Investment Management Inc	Mar 31, 2026	540.35K	$8.95M	+30.62%
American Century Companies Inc	Mar 31, 2026	515.36K	$8.53M	+26.13%
Us Bancorp \De\	Mar 31, 2026	510.23K	$8.45M	+134.56%
Focus Partners Wealth	Mar 31, 2026	482.39K	$7.99M	-14.17%
Lpl Financial Llc	Mar 31, 2026	474.21K	$7.85M	+33.04%
Jpmorgan Chase & Co	Mar 31, 2026	453.98K	$7.52M	+87.46%
Bleakley Financial Group, Llc	Mar 31, 2026	431.60K	$7.15M	+18.98%
Citigroup Inc	Jun 30, 2026	396.46K	$6.57M	+10.69%
Federated Hermes, Inc.	Mar 31, 2026	382.25K	$6.33M	+1.43%
Qrg Capital Management, Inc.	Jun 30, 2026	372.75K	$6.17M	+1.38%
Ethic Inc.	Jun 30, 2026	365.25K	$6.05M	+9.08%
Vestmark Advisory Solutions, Inc.	Mar 31, 2026	345.82K	$5.73M	+82.42%
Natixis Advisors, Llc	Mar 31, 2026	324.03K	$5.37M	+42.27%
Bank Of America Corp /De/	Mar 31, 2026	319.97K	$5.30M	-11.82%
Assetmark, Inc	Jun 30, 2026	314.69K	$5.21M	+38.25%
Raymond James Financial Inc	Mar 31, 2026	312.02K	$5.17M	+79.72%
Two Sigma Investments, Lp	Mar 31, 2026	311.70K	$5.16M	0.00%
Two Sigma Advisers, Lp	Dec 31, 2025	298.40K	$4.94M	+44.02%
Hantz Financial Services, Inc.	Mar 31, 2026	283.04K	$4.69M	+11.66%
Pathstone Holdings, Llc	Mar 31, 2026	241.29K	$4.00M	+11.52%
Clean Yield Group	Mar 31, 2026	238.37K	$3.95M	-8.60%
Mariner, Llc	Mar 31, 2026	234.99K	$3.89M	+25.23%
Sei Investments Co	Mar 31, 2026	229.94K	$3.81M	+20.26%
Trexquant Investment Lp	Mar 31, 2026	229.46K	$3.80M	0.00%
Cetera Investment Advisers	Mar 31, 2026	224.01K	$3.71M	+7.22%

Symbol: TAK
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Asia
Exchange: NYSE

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

Key Issues

Bullish view

Takeda’s first-quarter update says growth from core brands and newer products largely offsets expected declines in the mature portfolio, supporting continued portfolio renewal.

Bearish view

The same update confirms that mature products are declining, and the evidence does not show that newer products can more than offset that pressure.

Takeda Pharmaceutical Q1 Earnings Call Highlights

Analyst Consensus

See all

Buy

5 analysts

$17

Current

—

Low

$21

Average

—

High

Average target implies +26.58% versus the current price.

Earnings History

BeatMissNo estimate

Peers

argenx SE American Depositary SharesARGX · NASDAQ-GS$864.13